These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33972682)

  • 21. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
    Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
    Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma.
    Liu T; Yue X; Chen X; Yan R; Wu C; Li Y; Bu X; Han H; Liu RY
    Cell Oncol (Dordr); 2024 Aug; 47(4):1277-1294. PubMed ID: 38393513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
    Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
    Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.
    Zhang L; Wang X; Bullock AJ; Callea M; Shah H; Song J; Moreno K; Visentin B; Deutschman D; Alsop DC; Atkins MB; Mier JW; Signoretti S; Bhasin M; Sabbadini RA; Bhatt RS
    Clin Cancer Res; 2015 Apr; 21(8):1925-1934. PubMed ID: 25589614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a
    Yazbeck R; Jaenisch S; Squire M; Abbott CA; Parkinson-Lawrence E; Brooks DA; Butler RN
    Sci Rep; 2019 Mar; 9(1):4906. PubMed ID: 30894647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
    Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities.
    Varela-Calviño R; Rodríguez-Quiroga M; Dias Carvalho P; Martins F; Serra-Roma A; Vázquez-Iglesias L; Páez de la Cadena M; Velho S; Cordero OJ
    IUBMB Life; 2021 May; 73(5):761-773. PubMed ID: 33615655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
    Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
    BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
    Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
    Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
    Liu W; Ren D; Xiong W; Jin X; Zhu L
    J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
    Chen S; Cui L; Hu Q; Shen Y; Jiang Y; Zhao J
    Biochem Biophys Res Commun; 2020 Sep; 530(1):142-148. PubMed ID: 32828276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
    Dong Y; Manley BJ; Becerra MF; Redzematovic A; Casuscelli J; Tennenbaum DM; Reznik E; Han S; Benfante N; Chen YB; Arcila ME; Aras O; Voss MH; Feldman DR; Motzer RJ; Fabbri N; Healey JH; Boland PJ; Chawla M; Durack JC; Lee CH; Coleman JA; Russo P; Hakimi AA; Cheng EH; Hsieh JJ
    Eur Urol Focus; 2017 Dec; 3(6):590-598. PubMed ID: 28753786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.
    Makhov P; Sohn JA; Serebriiskii IG; Fazliyeva R; Khazak V; Boumber Y; Uzzo RG; Kolenko VM
    Br J Cancer; 2020 Dec; 123(12):1749-1756. PubMed ID: 32968206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth.
    Hollande C; Boussier J; Ziai J; Nozawa T; Bondet V; Phung W; Lu B; Duffy D; Paradis V; Mallet V; Eberl G; Sandoval W; Schartner JM; Pol S; Barreira da Silva R; Albert ML
    Nat Immunol; 2019 Mar; 20(3):257-264. PubMed ID: 30778250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance.
    Feng C; Li Y; Li K; Lyu Y; Zhu W; Jiang H; Wen H
    J Exp Clin Cancer Res; 2021 Sep; 40(1):308. PubMed ID: 34593007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
    D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
    Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
    Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
    Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis.
    Huang KB; Pan YH; Shu GN; Yao HH; Liu X; Zhou M; Wei JH; Chen ZH; Lu J; Feng ZH; Chen W; Han H; Zheng ZS; Luo JH; Zhang JX
    Cancer Lett; 2021 Dec; 523():121-134. PubMed ID: 34626691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of linagliptin on human immortalized podocytes: a cellular system to study dipeptidyl-peptidase 4 inhibition.
    Miglio G; Vitarelli G; Klein T; Benetti E
    Br J Pharmacol; 2017 May; 174(9):809-821. PubMed ID: 28177527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.